Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data

IASLC Journals Share Exciting Milestones on Metrics Journeys

In Brief for Oct. 26, 2022

In Brief for Nov. 9, 2022

In Brief for Dec. 21, 2022

IASLC Announces New JTO CRR Editor-in-Chief

ILCN Names New Associate Editors

In Brief for January 25, 2023